Introduction: Despite intensive research efforts, there is still no effective prophylactic vaccine available against HIV-1. Currently, substantial efforts are devoted to the development of vaccines aimed at inducing broadly neutralizing antibodies (bNAbs), which are capable of neutralizing most HIV-1 strains. All bNAbs target the HIV-1 envelope glycoprotein (Env), but Env immunizations usually only induce neutralizing antibodies (NAbs) against the sequence-matched virus and not against other strains. Areas covered: We describe the different strategies that have been explored to improve the breadth and potency of anti-HIV-1 NAb responses. The discussed strategies include the application of engineered Env immunogens, optimization of (bNAb) ep...
Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of acquired im...
Potent broadly neutralizing antibodies (bNAbs) targeting HIV-1 exhibit significant antiviral activit...
Abstract Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viru...
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive. There are...
The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1) strains poses a ...
Abstract The elicitation of broadly neutralizing antibodies (bnAbs) is considered crucial for an eff...
Abstract Despite enormous efforts no HIV-1 vaccine has been developed that elicits broadly neutraliz...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
A leading strategy for developing a prophylactic HIV-1 vaccine is the elicitation of antibodies that...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
Abstract The extreme HIV diversity posts a great challenge on development of an effective anti-HIV v...
The development of an effective HIV-1 vaccine must be considered one of the greatest biomedical cha...
© 2017 Dr. Hannah Alexandra Dolby KingAn effective prophylactic vaccine for HIV will likely require ...
Recent biological, structural, and technical advances are converging within the HIV-1 vaccine field ...
Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of acquired im...
Potent broadly neutralizing antibodies (bNAbs) targeting HIV-1 exhibit significant antiviral activit...
Abstract Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viru...
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive. There are...
The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1) strains poses a ...
Abstract The elicitation of broadly neutralizing antibodies (bnAbs) is considered crucial for an eff...
Abstract Despite enormous efforts no HIV-1 vaccine has been developed that elicits broadly neutraliz...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
A leading strategy for developing a prophylactic HIV-1 vaccine is the elicitation of antibodies that...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
Abstract The extreme HIV diversity posts a great challenge on development of an effective anti-HIV v...
The development of an effective HIV-1 vaccine must be considered one of the greatest biomedical cha...
© 2017 Dr. Hannah Alexandra Dolby KingAn effective prophylactic vaccine for HIV will likely require ...
Recent biological, structural, and technical advances are converging within the HIV-1 vaccine field ...
Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of acquired im...
Potent broadly neutralizing antibodies (bNAbs) targeting HIV-1 exhibit significant antiviral activit...
Abstract Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viru...